HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Consensus Recommendation of “Hold” by Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has earned a consensus rating of “Hold” from the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $20.8750.

A number of equities analysts recently issued reports on HCM shares. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd.

Institutional Investors Weigh In On HUTCHMED

A number of large investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its position in shares of HUTCHMED by 131.5% in the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock valued at $103,000 after acquiring an additional 4,378 shares in the last quarter. Ameriprise Financial Inc. raised its stake in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in HUTCHMED by 12.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after purchasing an additional 1,873 shares during the period. Bank of America Corp DE lifted its holdings in shares of HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Price Performance

Shares of NASDAQ:HCM opened at $13.85 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $19.50. The company has a 50 day moving average price of $14.71 and a 200 day moving average price of $14.96.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.50 by ($2.49). The business had revenue of $135.42 million during the quarter, compared to the consensus estimate of $290.50 million. As a group, equities analysts forecast that HUTCHMED will post 0.16 earnings per share for the current fiscal year.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.